Navigation Links
Wyeth Reports Earnings Results for the 2007 Fourth Quarter and Full Year
Date:1/31/2008

rrent business model and working with our management team to find approaches to help us operate more efficiently over the long-term, and continue as a driving force in global healthcare."

2007 Fourth Quarter and Full Year Product Highlights

Set forth below is a table of net revenue for Wyeth's principal products for the 2007 fourth quarter and full year together with the percentage changes from the comparable period in the prior year:

(UNAUDITED)

Three Months Ended Full Year Ended

12/31/2007 12/31/2007

Increase/ Increase/

($ in millions) (Decrease) ($ in millions) (Decrease)

Principal Products

Effexor $968 3% $3,794 2%

Prevnar 556 11% 2,439 24%

Enbrel (outside the

U.S. and Canada) 565 36% 2,045 36%

Protonix 461 10% 1,911 6%

Nutrition 393 28% 1,443 20%

Alliance Revenue (1) 321 (13)% 1,294 (3)%

Zosyn/Tazocin 292 17% 1,137 17%

Premarin Family 264 1% 1,055 0%

Centrum 204 13% 705 7%

Advil 186 8% 684 10%

(1) Alliance revenue reflects revenue to Wyeth derived from sales of

Enbrel (in the United States and Canada), Altace and the CYPHER stent.

Product Highlights

Enbrel(R) continued to post strong revenue growth during 2007. Enbrel sales in the United States and Canada, reported by Wyeth's marketing part
'/>"/>

SOURCE Wyeth
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Wyeth Sets Webcast and Conference Call for 2007 Third Quarter Earnings
2. Wyeth Announces $5 Billion Share Repurchase Program; Declares Increase in Common Stock Dividend
3. Wyeth Pharmaceuticals Acquires Haptogen Ltd. to Boost Biotechnology Drug Discovery
4. Wyeth Announces Election of New Principal Corporate Officer
5. Wyeth Declares Preferred Stock Dividend
6. Raven biotechnologies, inc. and Wyeth Pharmaceuticals Extend Evaluation Period of Selected Raven Antibodies
7. Wyeth Provides Update on Regulatory Review of Viviant (bazedoxifene)
8. Pfizer, Genentech, Amgen, Bayer, Wyeth, Abbott, Merck and Additional Leading Pharmaceutical Companies Participating During ExL Pharmas Fall Line Up!
9. Wyeth Will Pursue Claim for Damages Resulting From Teva Pharmaceuticals Launch of Generic Pantoprazole in Violation of PROTONIX Patent
10. Wyeth Consumer Healthcare Supports U.S. Food and Drug Administration Decision for Over-the-Counter Cough and Cold Medications in Children under Two Years of Age
11. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... Feb. 27, 2015 Bionomics Limited (ASX:BNO, ADR:BMICY) ... trial of BNC105 in patients with metastatic renal cancer ... Orlando, Florida . The data will be presented ... of Hope Comprehensive Cancer Center in California ... The new data identifies Ferritin and IL-8 as two ...
(Date:2/27/2015)... February 27, 2015 Cytokinetics, Incorporated (Nasdaq: ... February 28 with patients and health care advocates in ... Rare Disease Day®. Rare Disease Day is dedicated ... attention to the special challenges faced by patients with ... “Cytokinetics is proud to stand alongside patients and caregivers ...
(Date:2/26/2015)... 26, 2015 S&P Capital IQ (MHFI) announced ... coverage on MabVax Therapeutics Holdings Inc . ... stage biotechnology company focused on the development of vaccine ... the treatment of cancer. MabVax has discovered a pipeline ... immune responses generated by patients who have been immunized ...
(Date:2/26/2015)... , Feb. 26, 2015 /PRNewswire/ - SQI Diagnostics Inc. ... life sciences company that develops and commercializes proprietary technologies ... financial and operational results for the fiscal first quarter ... release are in Canadian dollars (CAD), unless otherwise stated. ... to win new business from our existing customers and ...
Breaking Biology Technology:New BNC105 Biomarker Data to be Presented at US Cancer Conference 2New BNC105 Biomarker Data to be Presented at US Cancer Conference 3New BNC105 Biomarker Data to be Presented at US Cancer Conference 4New BNC105 Biomarker Data to be Presented at US Cancer Conference 5Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 2Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 3Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 4Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 5Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 6S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 5SQI Diagnostics Reports First Quarter Financial Results 2SQI Diagnostics Reports First Quarter Financial Results 3SQI Diagnostics Reports First Quarter Financial Results 4SQI Diagnostics Reports First Quarter Financial Results 5SQI Diagnostics Reports First Quarter Financial Results 6
... BIOSAFE, Inc. has announced that it has ... solutions and entered into a commercialization agreement with ... BIOSAFE,s patented and exclusive antimicrobial polymer, HM4100.  The ... from harmful and degrading effects of bacteria, mold, ...
... Spanish . The researchers decided to embark ... are used by plants when they extract water from very ... swamps, for example, the plants are able to extract freshwater ... pressure should make quite the opposite happen", explains Professor Jos ...
... Dec. 13, 2010 Laureate Pharma, Inc., a ... announces the addition of Kathleen P. Bloch as ... to increase capital and provide a platform for ... include the development of a robust, interactive financial ...
Cached Biology Technology:Pittsburgh-based BIOSAFE Receives EPA Registration and Enters Into Commercialization Agreement with Union Springs Pharmaceuticals 2Pittsburgh-based BIOSAFE Receives EPA Registration and Enters Into Commercialization Agreement with Union Springs Pharmaceuticals 3A study analyzes the movement of tree sap 2Laureate Pharma Appoints Kathleen P. Bloch as Chief Financial Officer 2
(Date:2/24/2015)... 2015 Research and Markets ( ... "Global 2D Gesture Recognition Market 2015-2019" ... analysts forecast the Global 2D Gesture Recognition market ... the period 2014-2019 The increased demand ... one of the major trends in the market. ...
(Date:2/13/2015)... , Feb. 13, 2015 ACT ... company that aims to transform cancer genomic information ... that the company has raised US$ 8 million in ... Based in Taipei, Taiwan , ... ACTDrug™, ACTOnco™. With the aim to implement next ...
(Date:2/10/2015)... Feb. 10, 2015  Alere Inc. (NYSE: ALR), ... financial results for the quarter ended December 31, ... and President of Alere said, "We made substantial ... as the global leader in rapid diagnostics and ... Alere Health divestiture in early January enabled us ...
Breaking Biology News(10 mins):Global 2D Gesture Recognition Market 2015-2019 with Cognitec Systems, CogniVue, eyeSight Mobile Technologies & PointGrab Dominating 2ACT Genomics Raises $8 Million in its First Private Funding Round 2Alere Inc. Announces Fourth Quarter 2014 Results 2Alere Inc. Announces Fourth Quarter 2014 Results 3Alere Inc. Announces Fourth Quarter 2014 Results 4Alere Inc. Announces Fourth Quarter 2014 Results 5Alere Inc. Announces Fourth Quarter 2014 Results 6Alere Inc. Announces Fourth Quarter 2014 Results 7Alere Inc. Announces Fourth Quarter 2014 Results 8Alere Inc. Announces Fourth Quarter 2014 Results 9Alere Inc. Announces Fourth Quarter 2014 Results 10Alere Inc. Announces Fourth Quarter 2014 Results 11Alere Inc. Announces Fourth Quarter 2014 Results 12Alere Inc. Announces Fourth Quarter 2014 Results 13Alere Inc. Announces Fourth Quarter 2014 Results 14Alere Inc. Announces Fourth Quarter 2014 Results 15Alere Inc. Announces Fourth Quarter 2014 Results 16Alere Inc. Announces Fourth Quarter 2014 Results 17Alere Inc. Announces Fourth Quarter 2014 Results 18Alere Inc. Announces Fourth Quarter 2014 Results 19Alere Inc. Announces Fourth Quarter 2014 Results 20Alere Inc. Announces Fourth Quarter 2014 Results 21Alere Inc. Announces Fourth Quarter 2014 Results 22Alere Inc. Announces Fourth Quarter 2014 Results 23Alere Inc. Announces Fourth Quarter 2014 Results 24Alere Inc. Announces Fourth Quarter 2014 Results 25Alere Inc. Announces Fourth Quarter 2014 Results 26Alere Inc. Announces Fourth Quarter 2014 Results 27Alere Inc. Announces Fourth Quarter 2014 Results 28Alere Inc. Announces Fourth Quarter 2014 Results 29Alere Inc. Announces Fourth Quarter 2014 Results 30Alere Inc. Announces Fourth Quarter 2014 Results 31Alere Inc. Announces Fourth Quarter 2014 Results 32Alere Inc. Announces Fourth Quarter 2014 Results 33Alere Inc. Announces Fourth Quarter 2014 Results 34
... in the food industry at sublethal doses may be ... resistance in bacteria and enhancing their ability to form ... print in Applied and Environmental Microbiology . This ... phenomenon. The study was designed to test whether ...
... proteins that help convey electrical signals throughout the body may ... of a new Johns Hopkins study study published in ... using spider, scorpion and sea anemone venom. ... that are vital to our well-beingthey trigger action potentials, or ...
... far the most successful life form on Earth. As ... spaceflight, they don,t do too badly in microgravity either. ... cosmonauts who were stricken with infections during their flights. ... treatments against most harmful bacteria. But previous studies have ...
Cached Biology News:Improper use of biocides in food production may endanger public health 2Tiny proteins have outsized influence on nerve health 2Tiny proteins have outsized influence on nerve health 3Beating bacteria on Earth -- and in space 2Beating bacteria on Earth -- and in space 3Beating bacteria on Earth -- and in space 4